Taking the top 5 most frequently concomitant altered genes detected in lung cancer CTC/ctDNA samples (CSMD2, DMBT1, EGFR, RYR2 and NOTCH1) and breast cancer CTC/ctDNA samples (MTOR, KMT2C, EGFR, ERBB3 and USH2A) from our study, we applied this gene set to a curated database of lung (n=511) or breast (n=996) cancers (13–21) obtained from cBioPortal (13, 14) for survival analysis. This evidence concerns the gene MTOR and lung carcinoma.